drug
Desowen
Marketedupdated 6mo agoby Teva Pharmaceuticals USA Inc
Approvedcommunity read0 votes
indications
investigational
Psoriasis
all catalysts(0)
nothing on the calendar yet
Trials studying Desowen
- —Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)
- phase1A Food-Effect Study of Budesonide Delayed Release Tablet (D23A) in Healthy Chinese Participants
- phase2Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis
- phase3Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
- phase3A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
- phase1Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants
- phase3Budesonide/Formoterol Inhalation Powder in Adults With Asthma
- phase4A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 13, 2027
269 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Aug 13, 2027formulationUS 8460641269d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that